PubMed Health⌕ Search

Biomedical subjects

K R Stokes

Publications and source records attributed to K R Stokes.

20 records · Page 2Linked to original sources

In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors.

PURPOSE: The authors evaluated the effects of daunomycin (daunorubicin)--an analogue of doxorubicin--ethiodized oil, and arterial occlusion on an in vitro hepatoma analogue and on in vivo rat liver tumors. MATERIALS AND METHODS: A human Sk hepatoma cell monolayer sandwich system was used to determine uptake of 3H-daunomycin under normoxic/hypoxic conditions with use of autoradiography. Fluorescence microscopy was used to evaluate the biodistribution of doxorubicin in cell cultures (human Sk hepatoma and colon carcinoma). Microvascular flow adjacent to and within liver tumors and the intrahepatic effects of doxorubicin and ethiodized oil were studied with in vivo video microscopy on exteriorized rat livers containing peripheral hepatomas. RESULTS: Increased uptake of 3H-daunomycin by hepatoma cells occurred under hypoxic conditions. Intrahepatic arterial administration of ethiodized oil caused temporary occlusion of peripheral sinusoids following passage through arterioportal anastomoses. Tumors received portal venous and neovascular blood supply and ethiodized oil occluded but did not enter the narrow neovasculature perfusing the tumors. CONCLUSION: Hypoxia increases uptake of 3H-daunomycin by human Sk hepatoma and colon carcinoma cell cultures. Selective hepatic arterial occlusion (and perhaps the resultant hypoxia) may facilitate increased uptake of doxorubicin analogues into liver tumors. Hepatomas receive both arterial and portal venous blood supply, and ethiodized oil reaches the tumor via arterioportal anastomoses that perfuse the tumor periphery.

Animals↗

Percutaneous intraarterial thrombolysis: analysis of factors affecting outcome.

PURPOSE: The authors report results of high-dose thrombolytic therapy in native arteries and vein grafts and discuss the various factors affecting outcome. PATIENTS AND METHODS: In a retrospective study, the outcome of 82 high-dose urokinase infusions in 76 patients was examined. Comorbid risk factors as they relate to outcome were studied extensively with log-linear analysis. Positive thrombolytic outcome (PTO) is defined as complete thrombolysis of a previously occluded segment with restoration of antegrade flow augmented by angioplasty or operative intervention to clear symptoms for 30 days. RESULTS: The procedure resulted in a PTO in 63 of 82 instances (77%). The treatment was with urokinase alone in 39 cases (47%) and urokinase followed by surgery in 34 (41%), by angioplasty in four (5%), and by angioplasty in the proximal artery and peripheral vein grafting in five (6%). All stenoses associated with grafts were treated surgically. None of the following affected thrombolytic outcome: age of occlusion, heparin dose, catheter type, length or location of graft, or artery versus graft occlusion. The 30-day mortality was 6.1%, with a procedure-related mortality rate of 2.4%. Overall amputation rate was 18% (74% for patients in whom lysis failed by 30 days). CONCLUSION: The presence of at least one runoff vessel was the most important factor affecting outcome (PTO, 95%; P = .00001, chi 2). The most important comorbid risk factor for failed thrombolysis was coronary artery disease (P = .03, chi 2).

Angioplasty↗